Frontier Pharma First-In-Class Innovation in Hematological Cancers First-in-Class Innovation in Hematological Cancers | 页面 2

Analysis reveals that the hematological cancer pipeline is among the most innovative in the
industry, with 477 first-in-class products.
Over the past 15 years, the treatment of hematological malignancies has changed significantly,
thanks to the development of targeted therapies. These developments have been based on the
growing understanding of the signaling pathways involved in disease pathogenesis. A notable
example is the approval of Rituxan in 1997, which is used to treat multiple types of hematological
malignancies, including Non-Hodgkin’s lymphoma. Analysis indicates that the current pipeline is
following this trend of focusing on innovative, targeted therapies.
The first-in-class targets in the pipeline are numerous and varied. Cytokine signaling targets are
the most common, with a total of 548 across all stages of development, followed by kinases. These
target categories account for the majority of targeted immunotherapies, which are the primary
focus of current development activity within oncology. The other target families have far fewer
first-in-class and versatile first-in-class products, reflecting the strong interest and potential
versatility of cancer immunotherapies.
Related reports by Radiant Insights:
http://www.radiantinsights.com/catalog/pharmaceuticals-and-healthcare
Scope
- With 1,474 products in active development, the pipeline is considerably large. How will pipeline
innovation affect the future hematological cancer market?
- There are 477 first-in-class products in the hematological cancer pipeline. Which of these hold the
greatest potential to improve future disease treatment with regard to their molecular target?
- The majority of first-in-class products were identified to be in development for multiple
indications. Are versatile products likely to play a key role in the future treatment of hematological
cancer?
- Analysis of the history of strategic consolidations revealed an increasing amount of deal activity
and a large number of first-in-class products not yet involved in any deals. How do deal frequency
and value compare between target families and molecule types, and which first-in-class programs
have not yet been involved in a licensing or co-development deal?
Reasons to buy
- Understand the current clinical and commercial landscape. This includes a comprehensive study
of disease pathogenesis, diagnosis and prognosis, and the treatment options available.
Follow Us: